SAR442501

DRUG2 trials

Sponsors

Sanofi

Conditions

Osteochondrodysplasia

Phase 1

A First-in-human Single and Repeated Dose Escalation Study of SAR442501 in Healthy Adults Subjects

CompletedNCT05846009

SanofiOsteochondrodysplasia

Start: 2020-11-18End: 2022-01-12Updated: 2024-08-27

Phase 2

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia

TerminatedNCT06067425

SanofiOsteochondrodysplasia

Start: 2023-10-10End: 2025-02-12Updated: 2026-06-25

Related Papers

Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial.

2023-10-0211 citations